Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation
Completed
Medical University of South Carolina
Phase 4
2006-02-01
The purpose of this study is to compare the effectiveness of Acular LS® and Lotemax® in the
prevention of inflammation in the eye after cataract surgery. Acular LS is made by Allergan,
Inc. It is a nonsteroidal anti-inflammatory drug (NSAID) and is approved by the Food and Drug
Administration (FDA) for use following cataract surgery. Lotemax is made by Bausch & Lomb. It
is a steroid and is also approved by the FDA for use following cataract surgery.
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
Completed
Bausch & Lomb Incorporated
Phase 4
2006-11-01
To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry
eye.
It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the
stinging with cyclosporine administration and the dry eye signs and symptoms experienced
during the initiation of therapy.
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
Completed
Ophthalmic Consultants of Long Island
Phase 4
2006-11-01
To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry
eye.
It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the
stinging with cyclosporine administration and the dry eye signs and symptoms experienced
during the initiation of therapy.
Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
Completed
Bausch & Lomb Incorporated
Phase 2
2005-11-01
This was a single-center, randomized, double-masked, placebo-controlled, parallel-group,
4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects
were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo
(vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose
bilaterally either TID or QID according to randomization.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
